Biannual Screening for HCC Offered to Patients With Cirrhosis. Introducing Surveillance for Hepatocellular Carcinoma (HCC) in the Central Denmark Region Using Ultrasound and Alpha-Fetoprotein to Reduce HCC-Related Mortality in Patients With Compensated Non-Viral Cirrhosis

This study is evaluating a twice-yearly screening program — using ultrasound scans and a blood test (alpha-fetoprotein) — to detect liver cancer (hepatocellular carcinoma, or HCC) early in patients with liver cirrhosis (scarring of the liver) who do not have viral hepatitis. **You may be eligible if...** - You have been diagnosed with liver cirrhosis - You do NOT have a history of chronic hepatitis B or C - Your cirrhosis is compensated (no recent major complications like bleeding, uncontrolled fluid buildup, or confusion from liver failure; Child-Pugh score of 8 or less) - You are between 40 and 79 years old - Your expected life expectancy is at least 1 year - You have not previously been treated for liver cancer - There is no current suspicion of liver cancer **You may NOT be eligible if...** - You have cirrhosis caused by hepatitis B or C - You are already receiving follow-up care after liver cancer treatment - You are already suspected of having liver cancer Talk to your doctor to see if this trial is right for you.